Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

BACKGROUND: Glucose variability has been associated with cardiovascular outcomes in type 2 diabetes, however, the interplay between glucose variability, empagliflozin and cardiovascular death has not been explored. In the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of cardiovascular death...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cardiovasc Diabetol
मुख्य लेखकों: Ceriello, Antonio, Ofstad, Anne Pernille, Zwiener, Isabella, Kaspers, Stefan, George, Jyothis, Nicolucci, Antonio
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2020
विषय:
Original Investigation
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556977/
https://ncbi.nlm.nih.gov/pubmed/33050931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01147-9
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन